High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*

Desnick, 2001, α-Galactosidase A deficiency: Fabry disease, 3733 Elleder, 1990, Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease: report on a case simulating hypertrophic non-obstructive cardiomyopathy, Virchows Arch A Pathol Anat Histopathol, 417, 449, 10.1007/BF01606034 von Scheidt, 1991, An atypical variant of Fabry's disease with manifestations confined to the myocardium, N Engl J Med, 324, 395, 10.1056/NEJM199102073240607 Nakao, 1995, An atypical variant of Fabry's disease in men with left ventricular hypertrophy, N Engl J Med, 333, 288, 10.1056/NEJM199508033330504 Nakao, 2003, Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype, Kidney Int, 64, 801, 10.1046/j.1523-1755.2003.00160.x Sachdev, 2002, Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy, Circulation, 105, 1407, 10.1161/01.CIR.0000012626.81324.38 Utsumi, 2000, Fabry disease in patients receiving maintenance dialysis, Clin Exp Nephrol, 4, 49, 10.1007/s101570050061 Spada, 2002, Screening for Fabry disease in end-stage nephropathies, J Inherit Metab Dis, 25, S113 Desnick, 2002, Fabry disease: unregonized ESRD patients and effectiveness of enzyme replacement on renal pathology and function, J Inherit Metab Dis, 25, S116 Spada, 2003, Molecular study in 20 unrelated male patients with Fabry disease: the A143T genotype correlates with the late-onset end-stage nephropathy, J Inherit Metab Dis, 26, 171, 10.1023/A:1024433100257 Kotanko, 2004, Results of a nationwide screening for Anderson-Fabry disease among dialysis patients, J Am Soc Nephrol, 15, 1323, 10.1097/01.ASN.0000124671.61963.1E Rolfs, 2005, Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study, Lancet, 366, 1794, 10.1016/S0140-6736(05)67635-0 Eng, 2001, Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease, N Engl J Med, 345, 9, 10.1056/NEJM200107053450102 Schiffmann, 2001, Enzyme replacement therapy in Fabry disease: a randomized controlled trial, JAMA, 285, 2743, 10.1001/jama.285.21.2743 Wilcox, 2004, Long-term safety and efficacy of enzyme replacement therapy for Fabry disease, Am J Hum Genet, 75, 65, 10.1086/422366 Fan, 1999, Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor, Nat Med, 5, 112, 10.1038/4801 Frustaci, 2001, Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy, N Engl J Med, 345, 25, 10.1056/NEJM200107053450104 Desnick, 2002, Enzyme replacement and enhancement therapies: lessons from lysosomal disorders, Nat Rev Genet, 3, 954, 10.1038/nrg963 Fan, 2003, A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity, Trends Pharmacol Sci, 24, 355, 10.1016/S0165-6147(03)00158-5 Pagliardini, 2003, A simple and rapid approach for screening lysosomal storage disorders, J Inherit Metab Dis, 26, S1 Meikle, 2004, Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy, Pediatrics, 114, 909, 10.1542/peds.2004-0583 Li, 2004, Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening, Clin Chem, 50, 1785, 10.1373/clinchem.2004.035907 Meikle, 1999, Prevalence of lysosomal storage disorders, JAMA, 281, 249, 10.1001/jama.281.3.249 Garman, 2004, The molecular defect leading to Fabry disease: structure of human α-galactosidase, J Mol Biol, 337, 319, 10.1016/j.jmb.2004.01.035 Matsuzawa, 2005, Fabry disease: correlation between structural changes in α-galactosidase, and clinical and biochemical phenotypes, Hum Genet, 117, 317, 10.1007/s00439-005-1300-5 Desnick, 1973, Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes: α-galactosidase activities in plasma, serum, urine, and leukocytes, J Lab Clin Med, 81, 157 Eng, 1997, Fabry disease: thirty-five mutations in the α-galactosidase A gene in patients with classic and variant phenotypes, Mol Med, 3, 174, 10.1007/BF03401671 Yasuda, 2003, Fabry disease: characterization of α-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele, Hum Mutat, 22, 486, 10.1002/humu.10275 Eng, 1993, Nature and frequency of mutations in the α-galactosidase A gene that cause Fabry disease, Am J Hum Genet, 53, 1186 Sakuraba, 1992, Invariant exon skipping in the human α-galactosidase A pre-mRNA: A g+1 to t substitution in a 5′-splice site causing Fabry disease, Genomics, 12, 643, 10.1016/0888-7543(92)90288-4 Okumiya, 1995, α-Galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins, Hum Genet, 95, 557, 10.1007/BF00223869 Okumiya, 1995, Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease, Biochem Biophys Res Commun, 214, 1219, 10.1006/bbrc.1995.2416 Ishii, 2000, Role of Ser-65 in the activity of α-galactosidase A: characterization of a point mutation (S65T) detected in a patient with Fabry disease, Arch Biochem Biophys, 377, 228, 10.1006/abbi.2000.1743 Froissart, 2003, Fabry disease: D313Y is an α-galactosidase A sequence variant that causes pseudodeficient activity in plasma, Mol Genet Metab, 80, 307, 10.1016/S1096-7192(03)00136-7 Fabry, 1898, Ein Beitrag Zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa hemorrhagica Habrae), Arch Dermatol Syph, 43, 187, 10.1007/BF01986897 Anderson, 1898, A case of angiokeratoma, Br J Dermatol, 10, 113, 10.1111/j.1365-2133.1898.tb16317.x Meikle, 2003, Lysosomal storage disorders: emerging therapeutic options require early diagnosis, Eur J Pediatr, 162, S34, 10.1007/s00431-003-1348-y McCabe, 2004, Genetic screening: carriers and affected individuals, Annu Rev Genomics Hum Genet, 5, 57, 10.1146/annurev.genom.5.061903.175941 Grody, 2001, Laboratory standards and guidelines for population-based cystic fibrosis carrier screening, Genet Med, 3, 149, 10.1097/00125817-200103000-00010 Kaback, 2001, Screening and prevention in Tay-Sachs disease: origins, update, and impact, Adv Genet, 44, 253, 10.1016/S0065-2660(01)44084-3 Henthorn, 2004, Neonatal screening for sickle cell disorders, Br J Haematol, 124, 259, 10.1046/j.1365-2141.2003.04775.x Schulze, 2003, Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications, Pediatrics, 111, 1399, 10.1542/peds.111.6.1399 Wilcken, 2003, Screening newborns for inborn errors of metabolism by tandem mass spectrometry, N Engl J Med, 348, 2304, 10.1056/NEJMoa025225 Desnick, 2003, Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy, Ann Intern Med, 138, 338, 10.7326/0003-4819-138-4-200302180-00014